Hold On TG’s Program Stems From Existing – Not New – Concerns

‘Sub-par’ Disclosure Draws Analyst Finger Wagging

 
• By Alaric DeArment
  
Digital illustration of Cancer cell in colour background
TG disclosed a partial clinical hold on its program to develop Ukoniq/ublituximab in NHL and CLL • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Anticancer

More from Therapy Areas